Spontaneous intracerebral hemorrhage (ICH) represents a serious condition with high clinical severity, a narrow time window for bleeding reduction, and different ways of caring for patients. Treatment of this non-traumatic condition is a major challenge. In an issue of The Lancet, Joseph P. Broderick and colleagues present the results of the FASTEST study. This study tests the safety and efficacy of a potent hemostatic agent, intravenous recombinant factor VIIa. The agent is administered to patients within 2 hours of the onset of ICH. The study is a huge effort to improve early hemostatic treatment.